FBLN5 and lung carcinoma: Importantly, loss of fibulin-5 expression was found to be significantly associated with poor outcomes of lung cancer patients, including decreased overall survival (HR = 0.74; P = 9.7 × 10−5) (Fig. 1D), earlier first progression (HR = 0.68; P = 3.3 × 10−4) (Fig. 1E), and lower post-progression survival (HR = 0.75; P = 0.042) (Figure S1).